Phosphorylation of cMyBP-C Affects Contractile Mechanisms in a Site-specific Manner  by Wang, Li et al.
1112 Biophysical Journal Volume 106 March 2014 1112–1122Phosphorylation of cMyBP-C Affects Contractile Mechanisms in a
Site-specific MannerLi Wang,†‡ Xiang Ji,§ David Barefield,§ Sakthivel Sadayappan,§ and Masakata Kawai†*
†Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, Iowa; ‡School of Nursing, Soochow
University, Suzhou, Jiangsu, China; and §Department of Cell and Molecular Physiology, Health Sciences Division, Loyola University Chicago,
Maywood, IllinoisABSTRACT Cardiac myosin binding protein-C (cMyBP-C) is a cardiac-specific, thick-filament regulatory protein that is differ-
entially phosphorylated at Ser273, Ser282, and Ser302 by various kinases and modulates contraction. In this study, phosphoryla-
tion-site-specific effects of cMyBP-C on myocardial contractility and cross-bridge kinetics were studied by sinusoidal analysis in
papillary and trabecular muscle fibers isolated from t/t (cMyBP-C-null) mice and in their counterparts in which cMyBP-C contains
the ADA (Ala273-Asp282-Ala302), DAD (Asp273-Ala282-Asp302), and SAS (Ser273-Ala282-Ser302) mutations; the results were
compared to those from mice expressing the wild-type (WT) transgene on the t/t background. Under standard activating condi-
tions, DAD fibers showed significant decreases in tension (~50%), stiffness, the fast apparent rate constant 2pc, and its magni-
tude C, as well as its magnitude H, but an increase in the medium rate constant 2pb, with respect to WT. The t/t fibers showed a
smaller drop in stiffness and a significant decrease in 2pc that can be explained by isoform shift of myosin heavy chain. In the
pCa-tension study using the 8 mM phosphate (Pi) solution, there was hardly any difference in Ca2þ sensitivity (pCa50) and
cooperativity (nH) between the mutant and WT samples. However, in the solutions without Pi, DAD showed increased nH
and slightly decreased pCa50. We infer from these observations that the nonphosphorylatable residue 282 combined with phos-
phomimetic residues Asp273 and/or Asp302 (in DAD) is detrimental to cardiomyocytes by lowering isometric tension and altering
cross-bridge kinetics with decreased 2pc and increased 2pb. In contrast, a single change of residue 282 to nonphosphorylatable
Ala (SAS), or to phosphomimetic Asps together with the changes of residues 273 and 302 to nonphosphorylatable Ala (ADA)
causes minute changes in fiber mechanics.
INTRODUCTIONCardiac myosin binding protein-C (cMyBP-C) is a 140 kDa
thick-filament-associated protein (1) that plays both struc-
tural and functional roles in sarcomeres (2,3). Mutations
in the cMyBP-C gene (MYBPC3) cause >40% of familial
hypertrophic cardiomyopathy (FHC) (4), the leading cause
of sudden cardiac death in young adults. cMyBP-C differs
from the skeletal isoforms in that it contains multiple phos-
phorylation sites. These are phosphorylated in a site-specific
way by at least six kinases: protein kinase A (PKA) (5,6),
protein kinase C (PKC) (5), protein kinase D (PKD) (7),
Ca2þ/calmodulin-dependent protein kinases II (CaMKII)
(6), ribosomal s6 kinase (8), and glycogen synthase kinase
3b (GSK3b) (9). cMyBP-C is extensively phosphorylated
under basal conditions (10), but its phosphorylation level
decreases under pathological conditions (10–15). Despite
extensive research on cMyBP-C, the physiological role of
its phosphorylation is not well understood.
Three phosphorylation sites identified in mice and their
homologous sites in humans are: Ser273, Ser282, and Ser302
(6,14,16). These residues are located in the M domain
between domains C1 and C2. It was found that PKA phos-
phorylates all three sites, PKC phosphorylates Ser273 and
Ser302, and CaMKII phosphorylates only Ser282 (17). BeingSubmitted October 10, 2013, and accepted for publication January 23,
2014.
*Correspondence: masataka-kawai@uiowa.edu
Editor: David Warshaw.
 2014 by the Biophysical Society
0006-3495/14/03/1112/11 $2.00a substrate of PKA and PKC (5,6), cMyBP-C is thought to
be important in regulating myocardial contraction through
a b-adrenergic signaling mechanism (18). Mutation of the
three Ser residues to phosphorylation-deficient Ala results
in impaired cardiac function, reduced contractile reserve,
and cardiac hypertrophy in transgenic mice (19,20). In
contrast, mutation of Ser to the phosphor-mimetic Asp
does not impair cardiac function and results in a cardiopro-
tective effect (21).
The phosphorylation sites in cMyBP-C are functionally
unequal and hierarchically regulated (6). That is, the three
phosphorylation sites do not act independently, but coopera-
tively (22). Among these three sites, Ser282 appears to play a
central role, as evidenced by the inactivation of cMyBP-C
phosphorylation at other sites when Ser282 is mutated to Ala
(6,17). It may be the consequence of a conformational change
that makes other sites inaccessible to kinases (6). In a previ-
ous investigation, we studied the importance of Ser282 phos-
phorylation on cardiac morphology and function, using the
transgenic mouse model SAS (Ser272-Ala282-Ser302), in
which Ser282 was mutated to Ala (17). At the same time,
two additional mouse models, DAD (Asp273-Ala282-Asp302,
in which Ser273 and Ser302 were mutated to the phosphoryla-
tion-mimetic Asp), and ADA (Ala273-Asp282-Ala302), were
studied (17). It was found that the hearts of DAD mice, but
not those of their ADA or SAS counterparts, showed signifi-
cant hypertrophy, fibrosis, and myocyte disarray, mimicking
the t/t (null) phenotype (17). Based on these observations, wehttp://dx.doi.org/10.1016/j.bpj.2014.01.029
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cross-bridge kinetics. The objective of this studywas to deter-
mine the consequences of phosphorylation at different
cMyBP-C sites for myocardial contractility and cross-bridge
kinetics, using the ADA, DAD, and SAS mutant mice. The
wild-type (WT) cMyBP-C transgene was introduced on the
cMyBP-Cnull (t/t) background, and this cDNAwas subjected
to site-directed mutagenesis to generate ADA, DAD, and
SAS transgenes. The results from each mouse model were
compared with those from mice expressing the WT trans-
gene. Our results indicate that the cross-bridge kinetics are
significantly altered in mice carrying the DAD mutation,
and that this results in a reduction of isometric tension.MATERIALS AND METHODS
Animal models
The transgenic mouse models used in this study were reported in a previous
publication (17). The t/t mouse is a hypertrophic cardiomyopathy mutant in
which modifications to the carboxyl end of the cMyBP-C protein cause it to
be absent from sarcomeres (23). The strain referred to as WT is a transgenic
line in which the WT cMyBP-C gene was introduced into the t/t back-
ground. Three mutant transgenes were also created, in which Ser residues
of cMyBP-C at positions 273, 282, and 302 were either unchanged or
mutated to Ala or Asp to produce a phosphorylation-deficient or phosphor-
ylation-mimetic effect, respectively. In the mutant names, Ala is coded as
A, Asp is coded as D, and Ser is coded as S, in the standard way, and
each mutant is identified by the three-letter code: ADA (expressing
Ala273-Asp282-Ala302), DAD (Asp273-Ala282-Asp302), and SAS (Ser273-
Ala282-Ser302). Information on the number of mice used, including their
age and gender, is listed in Table 1. These animal experiments were in
accordance with the guidelines of the Institutional Animal Care and Use
Committees at Loyola University in Chicago and The University of Iowa,
as well as those listed in the Guide for the Use and Care of Laboratory
Animals published by the National Institutes of Health.Muscle preparations
Each mouse was euthanized through intraperitoneal injection of Na pento-
barbital at 50 mg/kg, and the heart was removed. The whole heart wasTABLE 1 Gender and age for the adult mice used in this study
Mouse model Gender Age (months)
WT Male 5.8
WT Female 4.5
WT Male 2.3
t/t Male 2.7
t/t Male 5.1
t/t Male 5.1
t/t Male 2.4
t/t Male 2.4
ADA Male 5.0
ADA Male 8.0
ADA Male 8.0
DAD Male 7.4
DAD Male 5.5
SAS Male 10.4
SAS Female 4.4
SAS Male 2.9perfused using the Langendorff system with perfusion buffer at 37C for
5 min. The hearts were then moved sequentially to Na skinning solution
for 15–30 min, K skinning solution for 30 min, and storage solution on
ice overnight. On the next day, the storage solution was replaced once.
The compositions of the solutions used have previously been reported
(24). The hearts were then shipped on ice to Iowa City, where they were
stored at 20C until used for biophysical studies. The experiments were
performed two days to four weeks after shipment. There were hardly any
changes in the performance, with respect to either isometric tension or
rate constants, during this period. In the cases of preparations for which a
change in one of these parameters was observed, we disposed of the data
rather than proceeding with further analysis. With these criteria, many of
the preparations were usable beyond four weeks.
The method used for the mechanical measurements has been described
previously (25); the compositions of the solutions are found in our earlier
report (24). In brief, papillary and trabecular muscle fibers from both ventri-
cles ~1mm in length and 100 mm in diameter were dissected and mounted on
the experimental apparatus by attaching their ends to two stainless steel wire
hooks using nail polish. One hook was connected to a length driver, and the
other to a tension transducer. Fibers were soaked for 3–5min in 600mL relax-
ing solution, followed by further skinning in the relaxing solution containing
1% Triton X-100 for 20 min. Fibers were then washed with the relaxing so-
lution and stretched to remove the slack. This procedure generally resulted in
a sarcomere length of 2.1–2.2mm, as judged by optical diffraction using aHe-
Ne laser (wavelength: 0.6328 mm) (25). Fiber length (L0) and cross-sectional
area were recorded at this time. All the solutions were applied twice (600 ml
each) to ensure that significant amounts of the old solution did not remain.Solutions
Each fiberwas tested in the standard activating solution, followed by the pCa-
tension and pCa-stiffness study. The standard activating solution contained
(in mM) 6 K2CaEGTA, 6.1 Na2H2ATP, 15 Na2CP (creatine phosphate),
6.6 MgAc2 (Ac, acetate), 8 K1.5H1.5Pi (phosphate), 13 NaAc, 83 KAc, 10
MOPS, and 80U/mLCK (creatine kinase); the ionic compositions of this so-
lution were pCa (–log10[Ca
2þ]) 4.55, Mg2þ 1 mM, and MgATP2- 5 mM, pH
7.00, and ionic strength (IS) was 200 mM (adjusted by KAc). The pCa-ten-
sion and pCa-stiffness relations were studied in two sets of solutions, 8Pi and
0Pi. The 8Pi solution is our standard activating solution, in which the total Ca
concentration was changed from 0.94 mM to 6 mM to produce pCa levels in
the range 7.00–4.55, respectively. The 0Pi solution did not contain added Pi,
and contained (in mM) 7 K2CaEGTA, 2 Na2H2ATP, 15 Na2CP, 3 MgAc2, 81
KAc, 10 MOPS, and 80 U/ml CK; the ionic compositions of this solution se-
ries were Mg2þ 0.78–0.89 mM and MgATP2 1.62 mM, pH 7.00, with IS
150 mM (Table 1 of Bubb et al. (26)). pCa was adjusted to 7.00–4.40 by
changing the total Ca concentration across the range of 1.1–7.0 mM, respec-
tively. The 0Pi solution has been used by many other investigators (27–31),
whereas we have been using the 8Pi solution (24,33–35).Sinusoidal analysis
The sinusoidal analysis is complementary to step analysis, in which length
changes are limited to a fraction of 1% of the total length; the details of this
analysis method are described in Wang et al. (24). In brief, when tension
reached a plateau, fiber length was oscillated in sine waves of varying fre-
quencies in the range 0.5–140 Hz at a small amplitude (0.125%, corre-
sponding to 1.3 nm at the half-sarcomere level). Both length (strain) and
tension (stress) time courses were digitized simultaneously using two
16-bit A/D converters without filtration. The complex modulus Y(f) was
defined as the ratio of the stress change to the strain change expressed
in the frequency domain. Y(f) consists of two components: the viscous
modulus (imaginary part of Y(f)) and the elastic modulus (real part of
Y(f)). For cardiac muscle, Y(f) was fitted to Eq. 1 to resolve into two expo-
nential processes, B and C (33):Biophysical Journal 106(5) 1112–1122
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Yðf Þ ¼ H  Bfi
bþ fiþ
Cfi
cþ fi
(1)
Processes B and C reflect the active interaction of myosin cross-bridges
with the thin filament, which leads to the transduction of chemomechanicalenergy, because they are absent in the rigor condition (33). Process B corre-
sponds to phase 3 of step analysis, which is amedium frequency-exponential
delay during which the muscle generates oscillatory work. Process C corre-
sponds to phase 2, which is a high-frequency exponential advance during
which themuscle absorbswork. In fast-twitch skeletalmuscle fibers, an addi-
tional exponential process Awas observed (33–35). In cardiac muscles, pro-
cess A is observed only at temperaturesR30C (see Fig. 3,C,F, I, L andO in
Lu et al. (36)). The study described here was performed at 20C to result in
two exponential processes, as shown by Eq. 1. The rate constants of delayed
tension 2pb, and fast tension recovery 2pc, are the apparent rate constants
of processes B and C, and B and C are their respective magnitudes (ampli-
tudes); H is the 0(zero) frequency stiffness. These were deduced by fitting
Y(f) to Eq. 1. The complex modulus Y(f) extrapolated to infinite (N) fre-
quency is: YN¼ H – Bþ C. YN corresponds to phase 1 of the step analysis,
and is loosely called stiffness in muscle mechanics literature.pCa-tension and pCa-stiffness studies
Tension increased when the pCa was changed sequentially from high to
low, as indicated in Fig. 1. The pCa-tension relationship was individually
fitted to the Hill equation:
Tension ¼ Tmax
1þ

Ca50
½Ca2þ
nH (2)
where Tmax is the maximum tension developed at saturating [Ca
2þ], Ca50 is
the Ca2þ concentration at half-saturation (apparent Ca2þ dissociation
constant), and nH is the Hill factor (describes cooperativity among con-
tractile proteins, including troponin, tropomyosin, myosin, and cMyBP-C)
based on tension. pCa50 ¼ –log10Ca50 indicates Ca2þ sensitivity. The pCa-
stiffness relationship was fitted to a similar equation:
Stiffness ¼ Smax
1þ

Ca50S
½Ca2þ
nHS (3)FIGURE 1 Slow time courses of length (A) and tension (B), demon-
strating the experimental protocol. This example is from an ADA fiber
preparation (0.9 mm in length and 87 mm in diameter). The amplitude of
sinusoidal oscillation was kept at 0.125% L0 in all frequencies, but because
the signal was filtered with a second-order low-pass filter (cutoff at 10 Hz),
the amplitude looks attenuated at higher frequencies (to the left). R, relax-
ing solution; A, standard activating solution. *2 indicates that the solution
was changed twice.
Biophysical Journal 106(5) 1112–1122where Smax is the maximum stiffness developed at saturating [Ca
2þ],
Ca50S is the Ca
2þ concentration at half-saturation, and nHS is the Hill
factor (which describes cooperativity determined based on stiffness).
pCa50S ¼ –log10Ca50S indicates Ca2þ sensitivity based on measurement
of stiffness.Identification of myosin heavy chain isoforms
To determine myosin heavy chain (MHC) isoform compositions, a- and
b-isoforms were separated on a 6.25% acrylamide Hoefer gel (99:1 acryl-
amide:bis-acrylamide) by SDS-PAGE. Gels were fixed in 10% acetic acid
followed by overnight staining with Sypro-Ruby. Gels were imaged and
the percentage of myosin isoforms was determined using Image J software.Statistics
In each experiment, >10 fibers were dissected from multiple hearts from
each mouse model (as indicated in Table 1) and studied. All data are ex-
pressed as the mean5 SE. One-way ANOVAwas performed to determine
the significance of the difference among test groups. Post hoc tests (least
significant difference) that allow pairwise multiple comparisons were
applied to locate the difference among groups. The MHC expression level
measured from SDS-PAGE was compared with Bonferroni post-hoc test
(see Fig. 8). A significant difference is defined as p% 0.05, and highly sig-
nificant as p % 0.01.RESULTS
All the values of biophysical parameters reported in this
section are listed in Table S1.Tension and stiffness during maximal Ca2D
activation
The cardiac fiber was soaked first in the relaxing solution
and then in the standard activating solution. When the
steady state in tension was achieved, the computer was
triggered to perform sinusoidal analysis and to collect the
fast-time-course data for length and tension signals as re-
ported (37). The slow time courses were traced by a pen
recorder, and typical records are shown in Fig. 1 A (length)
and Fig. 1 B (tension). The fiber was subsequently relaxed.
After this initial test, the fiber was activated in a series of
solutions containing increasing amounts of Ca2þ.
The above experiments were repeated for 11–38 fibers
from each mouse model and the results were averaged.
The complex modulus data were fitted to Eq. 1 to extract
two exponential processes. Their parameters were used to
calculate the elastic modulus YN, which is called stiffness.
Isometric tension and stiffness are plotted for five groups
of mice at pCa 4.55 in the 8Pi and 200IS solution (Fig. 2
A) and at pCa 4.40 in the 0Pi and 150IS solution (Fig. 2
B). These results demonstrate that tension and stiffness
were significantly lower (by ~48%) in the DAD group
than in the WT group (p < 0.01) in both solutions. It was
also noted that stiffness was significantly lower in the t/t
group in the 8Pi solution (Fig. 2 A), and in the ADA group
in the 0Pi solution (Fig. 2 B), than it was in the WT mice.
FIGURE 2 Isometric tension (Tmax in Eq. 2; left ordinate) and stiffness (Smax in Eq. 3; right ordinate) in 8Pi solution (A) and 0Pi solution (B) at saturating
[Ca2þ]. The 8Pi solution contained 8 mM Pi and its IS was 200 mM, whereas the 0Pi solution contained no added Pi and its IS was 150 mM. **p < 0.01 and
*p < 0.05 compared to WT. The number of experiments (n) in A is 31 for WT, 38 for t/t, 32 for ADA, 31 for DAD, and 27 for SAS; in B, n ¼ 14 for WT, t/t,
ADA, and DAD, and n ¼ 11 for SAS.
cMyBP-C and Cross-Bridge Functions 1115Tension was, as anticipated, 50–60% greater in the 0Pi
solution (Fig. 2 B) than in the 8Pi solution (Fig. 2 A). This
is due to the differences in both [Pi] and IS, as an increase
in either can decrease isometric tension in skeletal (38,39)
and cardiac (40,41) muscle fibers. Similarly, stiffness was
20–30% greater in the 0Pi solution than in the 8Pi solution.Cross-bridge kinetics
During the tension plateau of the standard activation, sinu-
soidal analysis was performed as described in Materials
and Methods, and the complex modulus data, Y(f), were
collected and plotted as discrete points in Fig. 3. These
data are equivalents of tension transients in response to
step changes in length. Fig. 3 includes plots of the elastic
modulus versus frequency (Fig. 3 A), the viscous modulus
versus frequency (Fig. 3 B), and the viscous modulus versus
the elastic modulus (Nyquist plots) (Fig. 3 C). Each Nyquist
plot shows two contiguous semicircles. Hence, the complex
modulus data can be resolved into two exponential pro-
cesses, B and C, as shown in Eq. 1. Fig. 3 reveals that
although the WT, t/t, ADA, and SAS groups had fairlyFIGURE 3 Averaged complex modulus data in the 8Pi solution. Data were plo
(imaginary Y(f)) versus frequency (B), and viscous modulus versus elastic modulu
27 for SAS. Solid lines represent Eq. 1 with best-fit parameters. In C, frequencsimilar complex modulus values, those of the DAD group
were considerably smaller, as evidenced by the considerably
smaller diameter of the semicircle in the Nyquist plot at fre-
quencies >20 Hz (Fig. 3 C).
The complex modulus data were fitted to Eq. 1, and the
best-fit data are shown in Fig. 3 as continuous curves.
Fig. 3 A shows that the elastic modulus remained small in
the low-frequency range (<7 Hz), reached its minimum
value at ~7 Hz (this frequency has been referred to as fmin
by some investigators (42)), and increased significantly in
the high-frequency range (>7 Hz). Fig. 3 B indicates that
the viscous modulus had small negative values in the low-
frequency range (<5 Hz), reached a shallow minimum at
~2 Hz, increased steeply in the range 5–25 Hz, reached its
maximum value at ~30 Hz, and decreased again in the
high-frequency range (50–140 Hz). The frequency at which
the viscous modulus is at its minimum approximates the
characteristic frequency, b, and that at which it is at its
maximum approximates the characteristic frequency, c. In
Fig. 3 B, it is evident that the frequency associated with
the maximum viscous modulus is shifted to the left in the
t/t group, indicating that 2pc is slower.tted as elastic modulus (real Y(f)) versus frequency (f) (A), viscous modulus
s (Nyquist plot) (C). n¼ 31 forWT, 38 for t/t, 32 for ADA, 31 for DAD, and
y increases in the clockwise direction; its value can be found in A and B.
Biophysical Journal 106(5) 1112–1122
1116 Wang et al.The fitting of the data in Fig. 3 to Eq. 1 yielded two
apparent rate constants, 2pb and 2pc, and their respective
magnitudes, B and C, as well as magnitude H, all of which
are plotted in Fig. 4 for the 8Pi solution at pCa 4.55, and in
Fig. 5 for the 0Pi solution at pCa 4.40. Fig. 4 A (left ordinate)
reveals that the rate constant 2pb for the DAD and SAS
groups was significantly larger than that for the WT mice,
and 2pb of the t/t and ADA groups was similar to that of
the WT group. The rate constant 2pc (Fig. 4 A, right ordi-
nate) for the t/t and DAD groups was significantly less than
that for the WT, but 2pc for the ADA and SAS groups was
similar to that for the WT. The different directions of the
two rate constants are not surprising, because each rate con-
stant reflects a different event in the cross-bridge cycle
(43,44). Fig. 4 B (left ordinate) indicates that magnitude B
for the t/t and SAS groups was larger than that for the WT
group (p < 0.05), and that B of the ADA and DAD groups
did not differ significantly from that of WT. Magnitudes C
and H were significantly smaller in the DAD group than in
the WT group (p < 0.05), but were similar across the other
groups (Fig. 4 B). In general, magnitude B was about half
of magnitude C but twice magnitude H in the 8Pi solution.
The apparent rate constants 2pb and 2pc deduced from
the 0Pi solution (Fig. 5 A) were ~1/5 and 1/3, respectively,
of those deduced from the 8Pi solution (Fig. 4 A). Similarly,
magnitude B was ~1/10, and magnitude C ~1/2, of the cor-
responding values in the 8Pi solution. Thus, the resolution of
processes B and C was much less in the 0Pi solution than in
the 8Pi solution. Because of this, the relative error bars
plotted in Fig. 5 are larger than those in Fig. 4. Due to the
small magnitude and large scatter of the data, the only sta-
tistical difference in the rate constants measured among
the five groups was a decreased 2pc in the t/t group. The
magnitudes B and C did not differ significantly among all
groups, but were somewhat lower in the DAD group. Mag-
nitudes H were significantly smaller in the DAD group than
in the WT group (p < 0.05). In all groups, magnitude H was
three times larger in the 0Pi solution than in the 8Pi solution.FIGURE 4 Parameters of exponential processes in the 8Pi solution (pCa 4.55
(B) Magnitudes of processes B (left ordinate) and C (right ordinate). (C) Magn
out in each group (for numbers of mice, see Table 1). n ¼ 31 for WT, 38 for t
compared to WT.
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pCa-tension and pCa-stiffness results are plotted in Fig. 6 (at
8Pi and 200IS) and Fig. 7 (at 0Pi and 150IS), as discrete
points after proper normalization. The data for each prepa-
ration were fitted to Eq. 2 (tension) or Eq. 3 (stiffness),
and the fitted parameters were averaged. The best-fit curves
are shown by solid lines in Figs. 6 and 7. The averaged
pCa50 and nH values are presented in Figs. 6, B and D,
and 7, B and D.
In the 8Pi solution (Fig. 6 B, left ordinate), pCa50 and nH
(Fig. 6 B, right ordinate) were centered at ~5.56 and ~6.0,
respectively, based on tension, and neither differed signifi-
cantly between the mutant and WT groups. Almost identical
results were obtained based on stiffness: pCa50Swas centered
at ~5.56, nHS was centered at ~6.0, and the values from the
five groups were not significantly different (Fig. 6 D).
In the 0Pi solution (Fig. 7, B and D), pCa50 was larger and
nH was smaller compared to their values in the 8Pi solution.
pCa50 and pCa50S centered at ~5.68, and nH and nHS
centered at ~2.7. Thus, it can be said that cardiac muscle
fibers are more sensitive to Ca2þ in the 0Pi solution than
in the 8Pi solution (by 0.12 pCa unit), but cooperativity in
the 0Pi solution is about half that in the 8Pi solution. These
results are consistent with our recent study on myosin regu-
latory light chain mutations in mice (24). In addition, values
among the five groups varied more extensively in the 0Pi
solution, and differed significantly in the 0Pi versus the
8Pi solution. The cooperativity was significantly larger in
the DAD group than in the WT group with respect to both
tension (p < 0.05) and stiffness (p < 0.01). Ca2þ sensitivity
was less in the DAD group than in the WT group with
respect to both tension (p ¼ 0.054) and stiffness (p < 0.05).Cross-bridge kinetics during partial activation
As indicated in Fig. 1, sinusoidal analysis was also per-
formed during the pCa study with 8Pi series solutions.). (A) Apparent rate constants 2pb (left ordinate) and 2pc (right ordinate).
itude H. Error bars represent the mean5 SE of 26–38 experiments carried
/t, 32 for ADA, 31 for DAD, and 27 for SAS. **p < 0.01 and *p < 0.05
FIGURE 5 Parameters of exponential processes in the 0Pi solution (pCa 4.40). (A) Apparent rate constants 2pb (left ordinate) and 2pc (right ordinate).
(B) Magnitudes of processes B (left ordinate) and C (right ordinate). (C) Magnitude H. n ¼ 14 for WT, t/t, ADA, and DAD, and n ¼ 11 for SAS. **p < 0.01
and *p < 0.05 compared to WT.
cMyBP-C and Cross-Bridge Functions 1117The rate constants 2pb and 2pc are plotted in Fig. 8. At
lower levels of activation (pCa R 6.0), the signal-to-noise
ratio was too small to resolve the cross-bridge kinetics.
Between pCa 5.8 and 5.4, 2pb increased steeply and 2pc
decreased steeply. Between pCa 5.4 and 4.5, 2pb decreased
slightly, and 2pc remained approximately the same. At all
pCa points, the order of 2pb and 2pc values among all
mouse groups remained the same as that shown in Fig. 4
A, with larger 2pb in the DAD and SAS groups, and smaller
2pc in the t/t and DAD groups.Myosin a- and b-isoform expression
Because it has been known that MHC isoforms affect the
apparent rate constant 2pc (45) and the shifts in isoform dis-
tribution have been observed in some transgenic mice (46),
we assessed the MHC isoform contents as described inMaterials and Methods. A representative gel is shown in
Fig. 9 A, and the analysis of the averaged data from three
gels is shown in Fig. 9 B. This analysis demonstrated that
WT mouse hearts contained 95.2 5 0.2% a-MHC (and
4.8% b-MHC), that ADA contained 86 5 6% a-MHC,
and that DAD contained 84 5 2% a-MHC; the values for
the latter two groups were not significantly different from
that of WT. In contrast, a-MHC was reduced to 57 5 4%
in t/t mice and to 74 5 3% in SAS mice, and b-MHC
increased significantly to 43 5 4%, and 26 5 3%,
respectively.Results excluding female mice
There may be a gender difference. Since we mixed results
from 14 male mice and two female mice (Table 1), we
constructed plots for the males only (Figs. S2–S7)FIGURE 6 Effect of pCa in the 8Pi solution in
five groups of mice. (A) pCa-tension curves normal-
ized to Tmax. (B) pCa50 (left ordinate) and nH (right
ordinate), as deduced by fitting the individual data
to Eq. 2, and averaging. (C) pCa-stiffness curves
normalized to Smax. (D) pCa50S (left ordinate) and
nHS (right ordinate), deduced by fitting the data to
Eq. 3, and averaging. In A and C, the data are shown
by discrete points, and the best-fit curves are shown
by solid lines. B and D do not reveal significant dif-
ferences in any of the parameters measured. n ¼ 17
for WT, 13 for t/t, 14 for ADA, 18 for DAD, and 12
for SAS.
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FIGURE 7 Effect of pCa in the 0Pi solution in
five groups of mice. Nomenclatures and conventions
used are as in Fig. 6. n ¼ 14 for WT, t/t, ADA, and
DAD, and n ¼ 11 for SAS. **p % 0.01, *0.01 <
p% 0.05, and (*)0.05 < p% 0.1 compared to WT.
1118 Wang et al.to examine whether this makes a difference. The figure
numbers, panel designations, and plotting conventions are
the same as those in the main text. When the data were
limited only to males, there were no substantial changes in
the results, but the error bars became larger because of the
smaller population. The exceptions were the larger active
tension (Figs. S2 A) and magnitudes B, C, and H (Fig. S4)
in the SAS group, in which the increase in tension and mag-
nitudes C and H became significant (p % 0.05), and B
became more significant (p % 0.01), compared to WT.DISCUSSION
The purpose of this study was to characterize the biophysi-
cal functions of cardiac muscle fibers that carry ADA, DAD,FIGURE 8 Apparent rate constants 2pb (A) and 2pc (B) plotted against pCa i
seriously contaminated with noise. n ¼ 17 for WT, 13 for t/t, 14 for ADA, 18 f
Biophysical Journal 106(5) 1112–1122SAS, and null (t/t) forms of cMyBP-C, and to thereby
advance our understanding of the role of cMyBP-C
phosphorylation. Tension and stiffness, together with the
apparent rate constants (2pb and 2pc) and the magnitudes
(B and C) of two exponential processes were studied. Rate
constants 2pb and 2pc are closely associated with the
elementary steps of the cross-bridge cycle (25), including
the binding of ATP and the release of Pi and ADP. These
parameters can be used to characterize contractile properties
and cross-bridge functions. pCa studies have been per-
formed to establish the Ca2þ sensitivity and cooperativity.
In this report, two sets of solutions were used. The first is
termed 8Pi solution and contains 5 mMMgATP2, 8 mM Pi,
and 200 mM IS, close to the composition in the cytosol
of contracting cardiomyocytes, which is reported to ben the 8Pi solution. Values at pCaR 6.0 are not included, because they were
or DAD, and 12 for SAS.
FIGURE 9 Expression of myosin a- and b-isoforms in each mouse
group. (A) A representative experiment. Isoforms detected using specific
antibodies after Sypro stained SDS-PAGE analysis. The molecular mass
of a-MHC is 223.565 kDa, and that of b-MHC is 222.849 kDa. (B) Frac-
tions of a- and b-MHC, as averaged from three gels (n ¼ 3), similar to
that represented in A, for WT and mutant cMyBP-C. Error bars are drawn
for each fraction. *p% 0.05.
cMyBP-C and Cross-Bridge Functions 11196–9 mM [Pi] (47), 4–6 mM [MgATP2] (47), and 215 mM
IS (48). The [ATP] and [Pi] data were obtained using the
chemical method in working hearts with adequate oxygena-
tion (47). Given that the physiological ionic strength of car-
diomyocytes has not been reported, the [IS] is based on
resting skeletal muscle fibers (48). The second solution is
termed 0Pi solution, and it has been used by many other in-
vestigators to characterize pCa-tension relationships (27–
30,49,50). This solution does not have any added Pi,
[MgATP2-] is 1.6mM, and IS is 150mM.Because of the con-
taminating Pi (mostly via ATP and phosphocreatine) and the
liberation of Pi fromATP hydrolysis, the actual [Pi] in the 0Pi
solution is in the range of 0.15–0.8 mM (51–53).
The tension values in Fig. 2 (8Pi solution) do not differ
from those previously reported in cardiac fibers (54) or
from those discussed in our previous work (24). The [Pi]
significantly influenced muscle contraction in many aspects.
The increased [Pi] caused less active tension and stiffness
(Fig. 2 A versus Fig. 2 B), larger rate constants and magni-
tudes B and C (Fig. 4, A and B, versus Fig. 5, A and B),
but less magnitude H (Fig. 4 C versus Fig. 5 C); nH became
larger and pCa50 became smaller (Fig. 6, B and D, versus
Fig. 7, B and D) regardless of mouse genotype in this study.
The differences between the mouse groups in either tension
or stiffness under 0Pi and 8Pi solutions were similar (Fig. 2).
Most of the significant changes in the cross-bridge kinetics
occurred in the 8Pi solution (Fig. 4). The trend was similar
in the 0Pi solution (Fig. 5), although this was not a signifi-
cant difference owing to the smaller magnitudes B and C,
which made the rate-constant data more scattered. In
contrast, with the pCa-tension study, the genotype differ-
ence was more clear in the 0Pi solution (Fig. 7, B and D)
than in the 8Pi solution (Fig. 6, B and D). The kinetics of
the cross-bridge cycle appear to be modified through the
thin filament activation mechanism; therefore, in partialactivation (pCa > 5.4), 2pb became slower and 2pc became
faster compared to the full activation (pCa% 5.0) (Fig. 8).
Rate constant 2pc became significantly larger than 2pb (up
to 20 times). These changes are similar to those found in
skeletal muscle fibers (55). The ~75% increase in 2pb and
the ~25% decrease in 2pc in DAD compared to WT
(Fig. 4 A) demonstrate the profound effect of DAD on the
elementary steps of the cross-bridge cycle.
Electron microscopy studies (56,57) suggest that
cMyBP-C is present only in the central 53% of the thick fil-
aments (9 stripes out of the total 17: C-zone), and absent in
the remaining 47% (8 stripes out of 17) (57). Therefore,
cross-bridges can be considered as a mixture of two
kinds—one-half (53%: C-zone) with cMyBP-C, and the
other half (47%) without cMyBP-C—arranged in parallel.
The role of cMyBP-C in modulating cardiac contractility
appears to be localized in the C-zone as shown by in vitro
motility assay (58). Our results demonstrate that isometric
tension and stiffness are significantly reduced (by ~48%) in
theDADfibers compared to theWTfibers (Fig. 2). Assuming
that the cross-bridges outside of the C zone (~47%) function
normally, the cross-bridges containing cMyBP-C DAD pro-
tein (~53%) must be almost inactive, or their function is
extremely diminished to ~5% (¼ 53%  48%). However, it
is also true that the cross-bridges that formwith theDADpro-
tein must be partially effective, as evidenced by the altered
kinetics of the rate constants 2pb and 2pc in the 8Pi solution
(Fig. 4 A). Therefore, it is possible that the DAD protein in-
fluences the cross-bridges beyond the C-zone.
In mouse cardiac muscles, PKA phosphorylates all three
sites (Ser273, Ser282, and Ser302), whereas PKC phosphory-
lates only two sites (Ser273 and Ser302) (17). The signifi-
cantly compromised tension-generating capacity and the
reduced number of cross-bridges in DAD mice, but not in
ADA and SAS observed in this study (Fig. 2), lead us to pro-
pose that PKC-mediated phosphorylation of cMyBP-C at
Ser273 and Ser302 either serves as a compensatory mecha-
nism that protects cardiomyocytes from overexertion of
the already dysfunctional heart, or results in maladaptive
contraction that ultimately compromises cardiac function.
Our biophysical data from DAD mice are consistent with
the cardiac hypertrophy, myocyte disarray, and interstitial
fibrosis previously observed (17). A recent study investi-
gated three additional cMyBP-C transgenic lines in mice:
DAA, AAD, and SDS, together with AAA, ADA, and t/t
(22). It was found that DAA and AAD mice were signifi-
cantly affected, showing more severe cardiac pathology
than t/t mice, with left ventricle dilation, interstitial fibrosis,
irregular cardiac rhythm, and sudden cardiac death (22).
Also, the sarcomere structure was seriously damaged in
DAD fibers (17). When these data and our results are com-
bined, we can conclude that a nonphosphorylatable Ala282
with phosphomimetic Asp273 and/or Asp302 (in AAD,
DAA, and DAD) are detrimental to cardiac structure and
function. We further conclude that the combination of theBiophysical Journal 106(5) 1112–1122
1120 Wang et al.phosphorylation pattern is critical in the function of cMyBP-
C.
An increase in active tension was previously found after
partial (60–70%) extraction of cMyBP-C (59); some inves-
tigators have reported accelerated cross-bridge kinetics and
increased power output in t/t compared toWTmice (60–63).
We are not certain about the reasons for these discrepancies,
but several differences in the experimental conditions may
have contributed. First, differences in the methods used
and the parameters investigated may account for the differ-
ences. In previous studies, the skinned fibers were produced
by homogenization of the thawed frozen heart (60,61,63),
but we generated skinned fibers from fresh hearts. It is
also worth noting that the accelerated cross-bridge kinetics
reported in previous studies were found to be significant
in partial activation (50% or 25% of maximal force) in the
absence of added Pi and in the 180 mM IS solution
(60–63), whereas our standard solution contained 8 mM
Pi and 200 mM IS. In addition, previous studies measured
the rate constants of stretch-induced force decay (krel) and
delayed force development (kdf) in stretch activation
(60,61), and the rate constant of force redevelopment (ktr)
through large release-restretch experiments (62,63). We
measured the rate constants of delayed tension, 2pb, and
of fast tension recovery, 2pc, through sinusoidal analysis
under near-isometric conditions.
Compared to the DAD group, the ADA and SAS groups
exhibited little change from the WT. In contrast to DAD,
100% phosphomimetic Asp282 within the context of non-
phosphorylation at positions 273 and 302 (ADA) appears
to have little effect other than a decreased stiffness in the
0Pi solution (Fig. 2 B). Because Ser282 plays an important
role in the phosphorylation of Ser273 and Ser302 (6,17), it is
reasonable to postulate that in the SAS mutation (with phos-
phorylation-deficient Ala282), the phosphorylation of Ser273
and Ser302 is significantly reduced. The smaller changes
in SAS compared to DAD suggest that when residue 282
cannot be phosphorylated, 100% phosphomimetic Asp273
and Asp302 (DAD) may be detrimental for cardiac function.
The SAS actually exhibited somewhat opposite effects to
DAD in active tension, and in magnitudes B and H; these
changes became significant when the data of one female
SAS mouse was excluded (Figs. S2 and S4). This does not
mean, however, that these parameters are lower in female
SAS mice, because there were not adequate data in females.
Several studies found that a 13–19% increase in b-MHC
expression (and a concomitant decrease in a-MHC expres-
sion) occurs in t/t mouse hearts (10,46,61). It has also
been observed that a 100% shift from a- to b-MHC reduces
2pc by ~75% without changing the isometric tension (45).
Thus, our observations on 2pc may be confounded by two
factors: a mutation in cMyBP-C and an MHC isoform shift.
For this reason, we studied the MHC isoform content
(Fig. 9). We found that our conclusions on DAD and ADA
are not significantly affected by the isoform shift, becauseBiophysical Journal 106(5) 1112–1122the b-MHC contents of DAD and ADA were small and
did not differ significantly from that of WT (Fig. 9 B). In
the case of t/t, there was a significant (43 5 4%) decrease
of the a-MHC content (Fig. 9 B), which could account for
much of the observed decrease in 2pc (42% in Fig. 4 A
and 33% in Fig. 5 A), because 75%  43% ¼ 32%. The
absence of cMyBP-C causes a problem in cardiac muscles,
as demonstrated by disorganized and damaged sarcomere
structures in t/t mice (17) and disordered thick filaments
with varying myosin heads extending from the backbone
of the thick filament, as well as an ~30% reduction in
maximal force after partial (29 5 3%) extraction of
cMyBP-C (64). The reduced 2pc in t/t mouse hearts
(Fig. 4 A) is consistent with the diminished left ventricle
function based on in vivo measurements (61,65,66),
depressed cross-bridge kinetics (67), slower shortening ve-
locity, and reduced power output (68,69). All of these lines
of evidence support the hypothesis that the absence of
cMyBP-C results in impaired myocardial contractility.
In the case of SAS, there was a significant (26 5 3%)
decrease in a-MHC contents (Fig. 9 B), which predicts a
20% (75%  26%) decrease in 2pc. Because the actual
decrease in 2pc was ~8% (Figs. 4 A and 5 A), the effect of
mutation in SAS may be to increase this rate constant by
~12% (20%  8%), and the two antagonizing effects may
compensate each other. Although there are no reports on
the effects of MHC isoforms on 2pb, it is possible that the
isoform content does not affect this parameter, given that lit-
tle change was observed in 2pb of t/t in two different solu-
tions (Figs. 4 A and 5 A). The increase in 2pb in DAD
must be due to this mutant form of cMyBP-C, because there
is no significant isoform shift (Fig. 9 B). The involvement of
isoform shifting does not modify our conclusions on tension,
stiffness, or magnitude parameters, because tension is not
sensitive to the shifting (45), and parameters YN, B, C, and
H are usually scaled with tension.CONCLUSION
This study investigated cardiac fiber contractility and
cross-bridge kinetics in transgenic mouse models carrying
cMyBP-C mutations that affect three different phosphoryla-
tion sites in its M-domain. Our investigation revealed that a
lack of cMyBP-C diminishes the rate constant of fast tension
recovery, 2pc, owing to the isoform shifting of MHC. Phos-
phomimetic Asp273 and Asp302 with a nonphosphorylatable
Ala substituted for residue 282 (DAD) significantly dimin-
ishes active tension and altered cross-bridge kinetics by
increasing the rate constant of delayed tension (2pb), and
decreasing the rate constant of fast tension recovery (2pc).
However, neither the single substitution of a nonphosphory-
latable residue 282 (SAS), nor the combination of nonphos-
phorylatable residues at 273 and 302 and the presence of a
100% phosphomimetic Asp282 (ADA), causes significant
changes in fiber tension and cross-bridge kinetics. In
cMyBP-C and Cross-Bridge Functions 1121conclusion, cMyBP-C influences cardiac contractility and
cross-bridge kinetics in a manner specific to the phosphory-
lation sites, and the nonphosphorylatable residue 282 com-
bined with phosphomimetic residues 273 and/or 302 is
detrimental to cardiomyocytes.SUPPORTING MATERIAL
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